Filter Results
Filter Results
General (94) Media Advisory (20) Partnerships (19) New Technologies (7) New Products (6) Acquisitions (5)
2026 (6) 2025 (5) 2024 (4) 2023 (8) 2022 (7) 2021 (13) 2020 (15) 2019 (21) 2018 (15) 2017 (16) 2016 (20)
English (130)
EnglishX
Reset Filters
   Loading...
Showing 1‐10 of 130
Media Advisory
02 Oct 2026
Lonza and Asimov Collaborate to Advance in vivo Lentiviral Vector Manufacturing
Collaboration connects Asimov’s genetic design and cell line technologies with Lonza’s process development, scale-up and GMP manufacturing expertise. Integrated approach...
Media Advisory
17 Aug 2026
Lonza Launches Rapid Custom Media Prototyping Service to Accelerate Early Bioprocess Development
Rapid access to custom liquid and powder media helps scientists move from formulation design to process decisions faster, while supporting a clearer path to future GMP...
Media Advisory
20 May 2026
Lonza and Oxford Nanopore Technologies Launch Direct RNA Sequencing Solution for GMP mRNA Quality Control
Nanopore sequencing combined with machine learning and dedicated workflows simplifies complex QC testing by measuring multiple critical quality attributes in one test Technology...
Media Advisory
12 May 2026
Lonza Expands AAV Offering with Xcite® AAV Stable Producer Cell Line Platform to Industrialize Viral Vector Manufacturing
New technology demonstrates superior performance versus transient transfection in clinically relevant customer gene of interest and engineered capsid, enabling scalable and...
Media Advisory
26 Mar 2026
Lonza Launches Media Development Lab in Singapore for Cell Culture Media Optimization
New media development services designed to optimize cell culture media development and identify robust, scalable media formulations driving cell culture performance and...
News Release
09 Mar 2026
Lonza and Genetix Biotherapeutics Extend Commercial Manufacturing Agreement for ZYNTEGLO™
Extended agreement will expand manufacturing capacity at Lonza Houston (US) to support growing demand for Genetix’s ZYNTEGLO™ (betibeglogene autotemcel), the only FDA-approved gene...
Media Advisory
11 Dec 2025
Lonza’s Cocoon® Platform Receives Advanced Manufacturing Technologies (AMT) Designation from the U.S. FDA
FDA granted Lonza’s Cocoon® Platform the Advanced Manufacturing Technologies (AMT) Designation  Designation expected to reduce regulatory uncertainty and promote adoption...
Media Advisory
27 Oct 2025
Lonza to Expand Bioscience Testing Offering With the Acquisition of Redberry
Lonza to acquire Redberry SAS, an innovative company specializing in rapid microbiology testing solutions Acquisition to include Red One™ solid-phase cytometry platform for...
Media Advisory
06 Oct 2025
Lonza Expands its TheraPEAK® Product Portfolio with the Addition of AmpliCell® Cytokine Range and TheraPEAK® 293-GT® Medium
AmpliCell® Cytokines enable cell expansion optimization, batch-to-batch consistency and easy transition from research to manufacturing TheraPEAK® 293-GT® Medium System aims to...
Media Advisory
23 Sep 2025
RION Engages Lonza to Scale Manufacturing Exosome Based Therapeutics
Lonza to support cGMP manufacturing of RION’s Purified Exosome Product™ (PEP™), a platelet-derived exosome-based drug candidate for chronic wound care and tissue regeneration...
1 2 3 4 ... 13 >